



POSTER PRESENTATION

Open Access

P10 - Antileukotriene treatment in children with bronchial asthma and allergic rhinitis

Maleyka Karimova

From 3rd Pediatric Allergy and Asthma Meeting (PAAM)
Athens, Greece. 17-19 October 2013

In recent years, scientists around the world are paying attention to the role of leukotrienes in the pathogenesis of bronchial asthma and allergic rhinitis. Leukotrienes – a group of biologically active substances produced from the metabolism of arachidonic acid. Increasing concentrations in the blood cause bronchoconstriction, increased bronchial secretion glands, increased vascular permeability. In allergic rhinitis, after exposure to an allergen, CysLTs are released from the nasal mucosa during both phases of the allergic reaction (early and late) and manifest symptoms of allergic rhinitis. These properties determine the pronounced therapeutic effect targeted therapy antileukotriene agents. We used antileukotriene treatment (Montel) of 56 children with asthma and 34 children with allergic rhinitis. Montel (ABDI IBRAHIM, Turkey) (active ingredient montelukast) – drug, which leukotriene –receptor antagonist, significantly reduces the manifestations of asthma and allergic rhinitis, thus improving pulmonary function and nasal breathing, reduces the number of exacerbations. In addition, advantage is ease of preparation and availability of the application. Montel application in pediatric practice ensures the stability condition of children with asthma and allergic rhinitis, and to reduce the dose of hormonal drugs (inhaled steroids). Also proved to be effective prophylactic use of the drug before physical exertion in cold air, and various stress effects. Montel is available in three dosages: Montel (4 mg) for children from 2 years to 5 years and Montel (5 mg) for children from 6 years to 14 years in the form of chewable tablets. Administered orally 1 chewable tablet 1 time a day in the evening. Reception of a preparation is not dependent of the meal. Montel (10 mg, tablets, film-coated) – for adults and children over 15 years of age should take 1 tablet (10 mg) 1 every day in the evening.

Published: 28 February 2014

doi:10.1186/2045-7022-4-S1-P65

Cite this article as: Karimova: P10 - Antileukotriene treatment in children with bronchial asthma and allergic rhinitis. *Clinical and Translational Allergy* 2014 **4**(Suppl 1):P65.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



Azerbaijan Medical University, Baku, Azerbaijan



© 2014 Karimova; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.